ANIX - Anixa Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ANIX

ANIXA BIOSCIENCES, INC.

NASDAQ

$3.71

▲ UP 3.34% (0.12)

KEY STATISTICS

Market Cap$126.23 M

52w High$5.46

52w Low$2.32

Dividend Yield—

Frequency—

P/E-11.97

Volume182.55K

Shares Out.34.02M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Amit Kumar

COMPENSATION 2026

Salary$815,170

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$102,414

Total$2,546,684

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 7, 1983

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$10.00

Target Low$3.50

Target Median$4.00

Target Consensus$5.83

UPCOMING EARNINGS

DateSep 9, 2026

DayWednesday

Rev. Est.—

SEP

WED

SPLIT RECORD

DATE	TYPE	RATIO
2015-06-26	Reverse	1:25
1996-06-18	Forward	2:1
1991-03-19	Forward	2:1
1987-09-16	Forward	5:4
1985-11-12	Forward	3:1

PRICE

$3.71 ▲ UP 3.34% (+$0.12)

OVERLAYS

About Anixa Biosciences, Inc.

https://www.anixa.com ↗

Anixa Biosciences develops innovative therapies and vaccines for oncology and infectious diseases, including CAR-T treatments, anti-viral drugs for COVID-19, and vaccines targeting breast and ovarian cancers.

INDUSTRY

Biotechnology

A PRODUCT ANIXA BIOSCIENCES, INC. IS KNOWN FOR

Liraltagene Autoleucel (lira-cel)

Anixa's CAR-T therapy for recurrent ovarian cancer, in Phase 1 trials, shows promising survival results and recent regulatory approval for dose escalation, forming a key part of its therapeutic pipeline.